Rheumatology Center of Delaware, LLC

Rheumatology Center of Delaware, LLC was paid $4.94M by Medicaid between Jan 2018 and Nov 2024, across 25 billing codes. Its largest line is J0129, Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) — 37% of everything it billed.

Compared with peers

Next to other Rheumatology Physician providers in Delaware

Rank by total paid#1 of 8

Median peer was paid$175K

This provider vs. median28×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	5,883	$248K
2019	4,825	$199K
2020	4,590	$1.04M
2021	4,811	$827K
2022	5,332	$1.01M
2023	4,156	$1.06M
2024incomplete	1,856	$554K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	37%	752	658	$1.82M
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	19%	1,146	597	$931K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	15%	443	340	$765K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	7.1%	8,448	7,870	$348K
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	5.7%	4,057	3,584	$281K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	5.1%	3,242	3,027	$252K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	4.2%	1,958	1,823	$207K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	4.0%	244	153	$197K
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	<1%	3,245	2,798	$36K
96401		<1%	401	341	$33K
96415		<1%	1,693	1,478	$29K
20610		<1%	515	334	$14K

13 more codes

J1030	Injection, methylprednisolone acetate, 40 mg	<1%	997	$10K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	447	$5K
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established)	<1%	302	$3K
J7050	Infusion, normal saline solution, 250 cc	<1%	2,862	$3K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	171	$991.01
99442		<1%	15	$611.62
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	104	$565.87
99070		<1%	227	$29.97
M1003	Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy	0%	48	$0.00
1170F		0%	31	$0.00
0540F		0%	61	$0.00
M1007	>=50% of total number of a patient's outpatient ra encounters assessed	0%	30	$0.00
G2112	Patient receiving <=5 mg daily prednisone (or equivalent), or ra activity is worsening, or glucocorticoid use is for less than 6 months	0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSHOCKLEY, PENNY (OFFICE MANAGER)